研究单位：[1]Peking University[2]301 Hospital Beijing, Beijing, China[3]302 Military Hospital of China Beijing, Beijing, China[4]Beijing Friendship Hospital, Capital Medical University Beijing, Beijing, China[5]Beijing Hospital Beijing, Beijing, China[6]Peking University International Hospital Beijing, Beijing, China[7]Peking University Peoples Hospital Beijing, Beijing, China[8]Fujian Medical University Union Hospital Fuzhou, Fujian, China[9]Fujian Tumor Hospital Fuzhou, Fujian, China[10]The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China[11]Zhongshan Hospital of Xiamen University Xiamen, Fujian, China[12]Guangdong General Hospital Guangzhou, Guangdong, China[13]Guangdong Hospital of Traditional Chinese Medicine Guangzhou, Guangdong, China[14]Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China[15]The First Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong, China[16]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China河北医科大学第四医院[17]Heilongjiang Cancer Hospital Harbin, Heilongjiang, China[18]Wuhan Union Hospital Wuhan, Hubei, China[19]Jiangsu People's Hospital Nanjing, Jiangsu, China[20]The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China[21]The First Hospital of Jilin University Chang chun, Jilin, China[22]The Second Hospital of Jilin University Chang chun, Jilin, China[23]The Second Affiliated Hospital-Dalian Medical University Dalian, Liaoning, China[24]Qinghai University Affiliated Hospital Xining, Qinghai, China[25]First Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China[26]Shandong Provincial Hospital Jinan, Shandong, China[27]Qingdao Municipal Hospital Qingdao, Shandong, China[28]The Affiliated Hospital of Qingdao University Qingdao, Shandong, China[29]Weifang People's Hospital Weifang, Shandong, China[30]Fudan University Cancer center Shanghai, Shanghai, China[31]Ruijin Hospital Shanghai, Shanghai, China[32]Shanghai Renji Hospital Shanghai, Shanghai, China[33]Zhongshan Hospital Shanghai, Shanghai, China[34]Shanxi Tumour Hospital Taiyuan, Shanxi, China[35]West China Hospital Chendu, Sichuan, China[36]Tianjin Medical University Cancer Hospital Tianjin, Tianjin, China[37]Tianjin Medical University General Hospital Tianjin, Tianjin, China[38]First Affiliated Hospital of Xinjiang Medical University Ürümqi, Xinjiang, China
With the introducing of neoadjuvant therapy, it becomes ever more important to evaluate the preoperative TNM (cTNM) stage accurately facilitating preoperative treatment as well as the adjuvant therapy.
At present, the recommendation of neoadjuvant chemotherapy varies among guidelines especially between eastern and western countries. According to the updated Japanese gastric cancer treatment guidelines (ver.5), neoadjuvant chemotherapy is the recommended standard procedure for patients with cT2-4 stages. However, the acknowledgement of preoperative therapy accompanied by the higher risk of overtreatment. As mentioned in JCOG1302-A, the overall precision rate in cT staging is 38.8%. Patients diagnosed with pI stages postoperatively account for 6.5% in cT3-4N+ treatment indicating more likely to avoiding the overtreatment comparing to patients with other cT stages.
Inspired by JCOG1302-A, this multicentre study prospectively collect data in preoperative TNM staging assessment using CT(computed tomography, CT) scan and the postoperative TNM (pTNM) staging according to histopathologically examination. By analyzing the accordance between the cTNM and pTNM, this study aims to evaluate the current accuracy of the cTNM staging in china, verifying the proportion of pI stages less than 5% in cIII stage diagnosis patients, learning the overtreating rate in neoadjuvant chemotherapy in China and furthermore, to discover the scope of beneficiaries for neoadjuvant chemotherapy.
